Begins Volume Coverage on MYGN, FNMA, ABX, and GALE

Follow this company

Companies Mentioned

12/03/2013 [ACCESSWIRE]

Whether it’s a bull or bear market, TrendingWallStreet has you covered. Take a few minutes to register with us at to get exclusive access to our free stock reports.

Myriad Genetics Inc. (NASDAQ: MYGN) shares closed down 9.31 percent on Monday on nearly 10 million shares traded. The stock traded in a range of 24.27 to 29.71 yesterday and had one of the highest volume increases on the NASDAQ. The Centers for Medicare & Medicaid Services announced that it would pay a fee of $1,438 to Myriad for each beneficiary who undergoes its BRACAnalysis test.

Get more information on Myriad Genetics Inc. and free access to the in-depth equity report at:

Federal National Mortgage Association (OTCBB: FNMA) shares closed up 6.42 percent on Monday with about 19.2 million shares traded. The pop in share price came after it was announced that Bank of America will pay $404 million to mortgage buyer Freddie Mac to settle all remaining claims over home loans sold in the previous decade.

Get more information on Federal National Mortgage Association and free access to the in-depth equity report at: 

Barrick Gold Corporation (NYSE: ABX) shares closed down 5.76 percent on Monday with nearly 20 million shares traded. The company fell into the red after along with other gold companies as gold prices tumbled to their lowest levels since July. The company is reportedly preparing to announce former Goldman Sachs president John Thornton's ascension to the role of chairman at this Wednesday's board meeting.

Get more information on Barrick Gold Corporation and free access to the in-depth equity report at:

Galena Biopharma, Inc. (NASDAQ: GALE) shares closed up 12.25 percent on Monday and hit a new 52-week high of 4.52 during intra-day trading. The stock traded a little over 12 million shares yesterday and was one of the biggest volume climbers on the NASDAQ. The stock has gained more than 87% since the start of November.

Get more information on Galena Biopharma, Inc. and free access to the in-depth equity report at:


Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.


Leave a comment...

Your Name